(4-氰基-3-甲氧基苯基)硼酸 | 677777-45-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氰基-3-甲氧基苯基)硼酸
• 中文别名: 4-氰基-3-甲氧基苯基硼酸
• 英文名称: 4-cyano-3-methoxyphenylboronic acid
• 英文别名: (4-Cyano-3-methoxyphenyl)boronic acid
• CAS: 677777-45-6
• 化学式: C₈H₈BNO₃
• mdl: MFCD10696655
• 分子量: 176.967
• InChiKey: YWZHJSBHFAFASK-UHFFFAOYSA-N

物化性质

• 沸点：
  417.6±55.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  73.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  6.1
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Cyano-3-methoxyphenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Cyano-3-methoxyphenylboronic acid
CAS number: 677777-45-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8BNO3
Molecular weight: 177.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (4-氰基-3-甲氧基苯基)硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 、 水 为溶剂， 反应 5.75h， 生成 (2-methoxy-4-(pyridin-2-yl)phenyl)methanamine
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE
  [FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE CDK ET LEUR UTILISATION THÉRAPEUTIQUE

  摘要：

  本发明涉及治疗化合物领域。更具体地说，本发明涉及某些取代的吡唑并[1,5-a]嘧啶-7-胺化合物PPA，这些化合物在抑制细胞周期依赖蛋白激酶（CDKs）方面具有选择性，特别是CDK12和/或CDK13，并且相对于CDK7具有选择性。除了选择性地抑制CDK12和/或CDK13外，这些化合物还作为选择性的Cyclin K降解剂，从而去除了CDK12和/或CDK13激活所需的关键辅因子；这赋予了额外的细胞效力和选择性。本发明还涉及包含这些化合物的制药组合物以及在体内外使用这些化合物和组合物来抑制CDK，特别是CDK12和/或CDK13，并治疗与CDK，特别是CDK12和/或CDK13相关的疾病，包括：由CDK，特别是CDK12和/或CDK13引起的疾病；由CDK突变，特别是CDK12和/或CDK13突变引起的疾病；由CDK过表达，特别是CDK12和/或CDK13过表达引起的疾病；由CDK上游通路激活，特别是CDK12和/或CDK13激活引起的疾病；由抑制CDK，特别是CDK12和/或CDK13抑制改善的增殖性疾病；癌症；病毒感染（包括艾滋病毒）；神经退行性疾病（包括阿尔茨海默病和帕金森病）；缺血；肾脏疾病；心血管疾病（包括动脉粥样硬化）；自身免疫性疾病（包括类风湿性关节炎）；以及由细胞翻译功能障碍引起的疾病（包括肌萎缩性侧索硬化症）。可选地，治疗还进一步包括与另一种活性剂的治疗（例如，同时或顺序治疗），该活性剂可以是DNA修复抑制剂、免疫检查点抑制剂、刺激免疫系统的剂、细胞周期检查点抑制剂、Her2阻断剂、转录抑制剂、细胞毒化学治疗剂等。

  公开号：

  WO2022263604A1
• 作为产物：
  描述：

  4-溴-2-甲氧基苯腈 在 正丁基锂 、 硼酸三异丙酯 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.5h， 以55%的产率得到(4-氰基-3-甲氧基苯基)硼酸
  参考文献：
  名称：

  [EN] AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES
  [FR] AZAINDOLES UTILES COMME INHIBITEURS DE JANUS KINASES ET D'AUTRES PROTEINES KINASES

  摘要：

  本发明涉及式(I)的化合物，它们是蛋白激酶的抑制剂。该发明还提供了包括该发明的化合物的药物组合物，以及使用这些组合物治疗各种疾病的方法。

  公开号：

  WO2005095400A1

文献信息

• [EN] N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS<br/>[FR] UTILISATION DE DÉRIVÉS D'INDOLE N-SUBSTITUÉS COMME MODULATEURS DES RÉCEPTEURS DES PGE2
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2017085198A1

  公开（公告）日：2017-05-26

  The present invention relates to derivativesof formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及公式(I)的衍生物，其中(R1)n，R2，R3，R4a，R4b，R5a，R5b和Ar1如描述中所述，其制备方法，其药学上可接受的盐，以及作为药物的用途，含有一个或多个公式(I)化合物的药物组合物，特别是作为前列腺素2受体EP2和/或EP4的调节剂的用途。
• Pd-Catalyzed Oxidative Aminocarbonylation of Arylboronic Acids with Unreactive Tertiary Amines via C–N Bond Activation
  作者：Yuvraj A. Kolekar、Bhalchandra M. Bhanage

  DOI：10.1021/acs.joc.1c00345

  日期：2021.10.15

  An efficient synthesis of tertiary amides from aryl boronic acids and inert tertiary amines through the oxidative carbonylation via C(sp3)–N bond activation is presented. This protocol significantly restricts the homocoupling biarylketone product. It involves the use of a homogeneous PdCl2/CuI catalyst and a heterogeneous Pd/C based catalyst, which promotes C(sp3)–N bond activation of tertiary amines

  提出了一种由芳基硼酸和惰性叔胺通过 C(sp 3 )-N 键活化的氧化羰基化有效合成叔酰胺的方法。该协议显着限制了同偶联二芳基酮产品。它涉及使用均相 PdCl 2 /CuI 催化剂和基于非均相 Pd/C 的催化剂，促进叔胺与芳基硼酸的C(sp 3 )-N 键活化。这个过程代表了一种无配体、无碱和可回收的催化剂，以及一种理想的氧化剂，如分子氧。
• Novel 3-Aryl Indoles as Progesterone Receptor Antagonists for Uterine Fibroids
  作者：Timothy I. Richardson、Christian A. Clarke、Kuo-Long Yu、Ying K. Yee、Thomas J. Bleisch、Jose E. Lopez、Scott A. Jones、Norman E. Hughes、Brian S. Muehl、Charles W. Lugar、Terry L. Moore、Pamela K. Shetler、Richard W. Zink、John J. Osborne、Chahrzad Montrose-Rafizadeh、Nita Patel、Andrew G. Geiser、Rachelle J. Sells Galvin、Jeffrey A. Dodge

  DOI：10.1021/ml100220b

  日期：2011.2.10

  We report the synthesis and characterization of novel 3-aryl indoles as potent and efficacious progesterone receptor (PR) antagonists with potential for the treatment of uterine fibroids. These compounds demonstrated excellent selectivity over other steroid nuclear hormone receptors such as the mineralocorticoid receptor (MR). They were prepared from 2-bromo-6-nitro indole in four to six steps using

  我们报告合成和表征新型3-芳基吲哚作为有力和有效的孕激素受体（PR）拮抗剂，具有治疗子宫肌瘤的潜力。这些化合物具有优于其他类固醇核激素受体（如盐皮质激素受体（MR））的选择性。它们是使用Suzuki交叉偶联作为关键步骤，由4至6个步骤由2-溴6-硝基吲哚制备的。化合物8f在大鼠子宫的孕酮拮抗作用的补体3模型中具有口服活性，并且在孕激素活性的McPhail模型中表现出部分拮抗作用。
• [EN] HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEUR EMPLOI EN TANT QU'INHIBITEURS DE L'ACTIVITÉ DE PI3K
  申请人：AMGEN INC

  公开号：WO2012003283A1

  公开（公告）日：2012-01-05

  Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

  含有取代的双环杂环芳基和含有它们的组合物，用于治疗一般炎症、关节炎、风湿病、骨关节炎、炎性肠道疾病、炎性眼部疾病、炎性或不稳定膀胱疾病、牛皮癣、带有炎症成分的皮肤疾病、慢性炎症性疾病，包括但不限于自身免疫疾病如系统性红斑狼疮（SLE）、重症肌无力、类风湿关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化症、Sjögren综合征和自身免疫性溶血性贫血，包括各种过敏症状的过敏症，本发明还提供了用于治疗由p110活性介导、依赖或与之相关的癌症的方法，包括但不限于白血病，如急性髓细胞白血病（AML）、骨髓增生异常综合征（MDS）、骨髓增生性疾病（MPD）、慢性髓细胞白血病（CML）、T细胞急性淋巴细胞白血病（T-ALL）、B细胞急性淋巴细胞白血病（B-ALL）、非霍奇金淋巴瘤（NHL）、B细胞淋巴瘤和实体肿瘤，如乳腺癌。
• [EN] TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES<br/>[FR] TRIAZOLOPYRIDINES EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASE POUR LE TRAITEMENT DE MALADIES DU DERME
  申请人：LEO PHARMA AS

  公开号：WO2010069322A1

  公开（公告）日：2010-06-24

  The present invention relates to a compound according to formula I, wherein R1, R2 and A are as defined herein, which exhibit PDE4 inhibitory activity and may be used in the treatment of inflammatory diseases or autoimmune diseases, in particular inflammatory or proliferative dermal diseases.

  本发明涉及一种符合式I的化合物，其中R1、R2和A如本文所定义，具有PDE4抑制活性，可用于治疗炎症性疾病或自身免疫性疾病，特别是炎症性或增生性皮肤疾病。